Moreover, ABT-239 is a potent H3 histamine receptor antagonist, presenting stimulant and nootropic effects, and has been investigated as a treatment for attention deficit hyperactivity disorder, Alzheimer’s disease, and schizophrenia [23]. Here, HRH3 is linked to early-onset autosomal dominant Alzheimer disease.